Guoqing Li

Vendite & Marketing presso Golden Maple Leaf Enterprises, Inc.

Health Technology

Consumer Services

Posizioni attive di Guoqing Li

Società	Posizione	Inizio	Fine
Golden Maple Leaf Enterprises, Inc.	Vendite & Marketing	27/07/2012	-
Golden Maple Leaf Enterprises, Inc.	Corporate Officer/Principal	23/05/2011	27/07/2012

Società	Posizione	Inizio	Fine
Welichem Biotech, Inc. Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada.	Direttore/Membro del Consiglio	21/10/2010	25/12/2012
	Presidente	25/12/2012	01/01/2016
	Independent Dir/Board Member	23/05/2011	01/01/2016

University of International Trade & Finance

Undergraduate Degree

Distribuzione geografica

Canada	3
Cina	2

Posizioni

Director/Board Member	1
Chairman	1
Independent Dir/Board Member	1

Settori

Health Technology	2
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	2
Welichem Biotech, Inc. Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada.	Health Technology
Golden Maple Leaf Enterprises, Inc.

Aziende private

Health Technology

Golden Maple Leaf Enterprises, Inc.